{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["revumenib","venetoclax"]],"indication":"acute myeloid leukemia with MRD","name":"NCT06284486","nct_id":"NCT06284486","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06284486. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants may receive the combination of venetoclax and revumenib for up to 1 year, and then 1 more year of venetoclax alone. You will no longer be able to take the study drug(s) if the disease gets worse or if intolerable side effects occur. Participants will take venetoclax by mouth on 1 time a day at about the same time each day, on Days 1-14 of each cycle. Take each dose with about 1 cup of water within 30 minutes after a meal, preferably breakfast.","label":"Venetoclax + Revumenib","type":"EXPERIMENTAL"}],"collaborators":["Syndax Pharmaceuticals","AbbVie"],"completion_date":{"date":"2028-12-30","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia"],"enrollment":{"count":8,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Venetoclax","otherNames":["ABT-199","GDC-0199"],"type":"DRUG"},{"name":"Revumenib","otherNames":["SNDX-5613"],"type":"DRUG"}],"last_update":"2026-09-18","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Safety and adverse events (AEs)","timeFrame":"Through study completion; an average of 1 year."}],"references":[],"start_date":{"date":"2024-09-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib","url":"https://clinicaltrials.gov/study/NCT06284486"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06284486"}